Renibus Therapeutics to Showcase Innovations at Needham Virtual Healthcare Conference Renibus Therapeutics will participate in the upcoming Needham Virtual Healthcare Conference from April 13-16, 2026, showcasing its innovative therapies.

Renibus Therapeutics to Showcase Innovations at Needham Virtual Healthcare Conference #USA #Southlake #Renibus_Therapeutics #RBT-1 #Veverimer

Renibus Therapeutics to Present Key Developments at the 36th Annual Oppenheimer Life Sciences Conference Renibus Therapeutics is set to present vital updates at the Oppenheimer Life Sciences Conference on February 25-26, 2026. Discover their advancements in biopharmaceuticals.

Renibus Therapeutics to Present Key Developments at the 36th Annual Oppenheimer Life Sciences Conference #United_States #Southlake #Renibus_Therapeutics #RBT-1 #Veverimer

Renibus Therapeutics Secures FDA Orphan Drug Designation for Veverimer as Treatment for Anti-glomerular Basement Membrane Disease Renibus Therapeutics has received FDA Orphan Drug Designation for veverimer, aimed at tackling anti-glomerular basement membrane disease, a rare kidney condition.

Renibus Therapeutics Secures FDA Orphan Drug Designation for Veverimer as Treatment for Anti-glomerular Basement Membrane Disease #United_States #Southlake #Anti-GBM #Renibus_Therapeutics #Veverimer

Renibus Therapeutics to Showcase Innovations at Oppenheimer's 35th Annual Healthcare Life Sciences Conference Renibus Therapeutics will participate in Oppenheimer's 35th annual healthcare conference, highlighting its innovative treatments for cardiac and renal diseases.

Renibus Therapeutics to Showcase Innovations at Oppenheimer's 35th Annual Healthcare Life Sciences Conference #USA #Southlake #Renibus_Therapeutics #RBT-1 #Veverimer

Renal grand rounds virtual on Monday Dec 7 at 5pm on Metabolic Acidosis and #Veverimer
David A. Bushinsky, MD, Professor of Medicine, University of Rochester School of Medicine @UrmcNephrology